Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
streptococcus pneumoniae type 19f capsular polysaccharide diphtheria crm197 protein conjugate antigen
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine component consisting of saccharides from the capsular antigens of Streptococcus pneumoniae serotype 19F. These saccharides are purified, chemically activated, and conjugated to the CRM197 carrier protein—a nontoxic variant of diphtheria toxin derived from Corynebacterium diphtheriae strain C7 (β197). This glycoconjugate is used in pneumococcal conjugate vaccines to enhance immune response and protection against invasive pneumococcal disease caused by serotype 19F. The mechanism of action involves stimulating the immune system to produce antibodies specific to the S. pneumoniae type 19F capsule, thereby providing active immunity[1][3].
- Brand names
- PrevnarPrevnar 13Prevnar13Prevnar-13Vaxneuvance
- Other names
- Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)MHC II (Major histocompatibility complex class II receptor)TCR-CRM197 (CRM197-specific T-cell receptor)
Beyond the preview
Go deeper on streptococcus pneumoniae type 19f capsular polysaccharide diphtheria crm197 protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on streptococcus pneumoniae type 19f capsular polysaccharide diphtheria crm197 protein conjugate antigen.